NBS SEEKING ALPHA ARTICLE //NeoStem: The Best Upside In An

New Post Public Reply Private Reply Replies (0) Message Board

Oct 9, 2012 at 9:19 AM

[b]NBS >> SEEKING ALPHA ARTICLE //NeoStem: The Best Upside In An Innovating Space[/b]
October 7, 2012
by: Henry Kawabe
| about: NBS, includes: BAX, CUR, OSIR, STEM
Disclosure: I am long NBS. (More...)

There is one change in the medical arena that investors are going to have to embrace, or at least accept: cell
therapy. In 2012, some of the best performing stocks in biotechnology have been in cell therapy. Already, we have
crossed a number of barriers. We've seen the first approved product with a cell therapy as a main component: Osiris
Therapeutics' (OSIR) Prochymal. Shares of Neuralstem (CUR) have nearly doubled in the last month alone as its
cell therapy showed a benefit of motor function in paralysis, a benefit never before reached. StemCells (STEM) has
also been a big-time performer following data that its cell therapy restored memory and enhanced synaptic function in
Alzheimer's disease. And if that's not enough, Baxter (BAX) recently reached endpoints never before conquered,
increasing exercise capacity and reducing angina due to chronic myocardial ischemia. The takeaway: It has been an
incredible year, and with such breakthrough data, it is only getting better.
In biotechnology, we've seen a number of novel therapeutics with crucial data as we inch closer to curing and
effectively treating life-threatening diseases. Cell therapy has been at the forefront of this movement - it has provided
proof of concept curing some of today's most deadly degenerative diseases - but is still in its early stages of
development.
With only one approved product that has a cell therapy as its main component, the potential for new treatments and
the outlook for those treatments is at an all-time high. The valuation for companies in this space is particularly
attractive, perhaps greater than in any other industry within biotechnology. The reason for attractive valuations is due
to skepticism among some who have yet to embrace the benefits of cell therapy. These people may believe that we'll
never see a large diversified product line of cell therapies, or that regulators will never accept the benefits of cell
therapy. However, this argument doesn't make sense, because countries around the globe are spending more on cell
therapies than at any point in our history. There is a significant cost benefit to cell therapies, not to mention
efficiency, that will replace inefficient therapeutics that are being used to treat degenerative diseases. For this reason,
we will see approvals in the cell therapy arena. We will see cheaper and more efficient therapies to treat diseases
that have limited or no current treatments, and this will occur because of clinical results, and over a period of several
years.
So how should investors play the growth of this space? Investors could invest in a company such as CUR or STEM.
But these companies are still early in the clinical process, and are more likely to benefit from the approvals of other
cell therapies; they will trade with far less upside than later-stage companies with similar valuations. You could invest
in the first approved cell therapy and OSIR. However, its product Prochymal is more of a "door opener" and not a
large revenue-producing product. The difficult aspect to finding a good investment is that there are a lot of cell therapy
companies with a lack of diversification-or only one significant product of growth-and we must assume that, despite
their promise, it may take a few years for cell therapies to gain full acceptance and reach full potential. So after
searching throughout the entire space, and reading 100s of reviews, business plans, and assessing market potential,
I feel confident that the best play in the space is NeoStem Inc. (NBS).
NeoStem
NeoStem is a $105 million market capitalization company with expertise and a presence that stretches far beyond
the norm of cell therapy and developmental-stage companies. The company operates in several segments, with a
diversified presence in the space, and has been a great investment in 2012, with an 81% return over the last six
months. The stock has returned a gain of more than 10% over the last month, but is now trading very close to its
support, therefore indicating short-term upside. Unlike most biotechnology companies of its size, NeoStem has

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cracking the Last-Mile 'Fragmentation Tax' Challenge

Tackling Last-Mile Delivery Woes It's like trying to put a square peg in a round hole. That's what last-mile delivery feels like right now with the burden we're seeing in EMEA—costs shooting up by 9% just this past year. Anyone in logistics knows that red ink doesn't just dry up on its own. According to FarEye, 96% of companies are coughing up more dough per delivery,...

California Exodus: Companies Flee Amid Wealth Tax Fears

Businesses Escaping the Golden State Proposition 40—the looming specter over California's business landscape. This so-called billionaire tax has stirred quite the storm, and from where I'm sitting, it's no surprise folks are heading for the exits. Cummings & Cummings Law reports a jaw-dropping 12-fold increase in companies scooting out of California and making a beeline...

Northern.tech Enhances Product Software Control & Security

The Evolution of Product Software Management Over in Palo Alto, Northern.tech has just flipped the switch on something pretty significant—component orchestration in their Mender solution. This isn't just your run-of-the-mill software update. They're talking about managing software across the entire system of a connected product. You know, pulling all the strings at...

Proterra's New Hire Targets Credit Expansion Ambitions

In the high-stakes world of leveraged finance, it's not always easy to stand out. Yet here we are, with Proterra Investment Partners snagging a seasoned vet, Eric Rogowski, for their credit squad. This ain't just window dressing; we're talking about real moves to beef up Proterra’s credit origination capacity—especially in the food, beverage, and agribusiness sectors....

Patriot Growth Welcomes Rajeev Jain: Operational Excellence

Shifting Gears: Patriot Growth's New Leadership Turn When it comes to tightening the ship and pointing towards uncharted waters, new leadership can be the key. This couldn't be more true for Patriot Growth Insurance Services as they welcome Rajeev Jain aboard as their latest Chief Operating Officer. This move is all about reinforcing their commitment to operational...

It'Sugar Faces Class Action Over Employee Break Violations

It'Sugar Faces Class Action Over Employee Rights Looks like the sugar rush turned into a legal headache for It'Sugar, a renowned candy retailer, as they're now tangled up in a class action lawsuit. This one's not just about spilled sprinkles—it's about alleged deep-rooted violations of California's labor laws. The Zakay Law Group, a labor law outfit outta San Diego, has...

Trip.com Drives Sustainability with New Travel Impact Tool

Sustainability Takes Center Stage in Travel Plans So here's the deal: Traveling isn't just about snapping pictures of breathtaking views or rounding up souvenirs anymore. These days, people are increasingly keen on ensuring their trips don't leave a hefty carbon footprint. With the release of Trip.com's 2026 Sustainable Travel Consumer Report, it's clear that the winds...

Duolingo Faces Securities Fraud Lawsuit: Key Deadline Looms

Duolingo Finds Itself in Deep Waters Did you ever think the darling of language apps, Duolingo, would be staring down the barrel of a securities fraud lawsuit? Well, here we are. The company's tangled up in a legal web over alleged shifty business practices, and investors who bought Duolingo Class A stock between May 2, 2025, and February 26, 2026, are at the center of...

Lektra Unveils EdgeStart: Green Earnings from AI

AI and Solar Power: A New Revenue Stream Lektra's fresh off the blocks with EdgeStart, an AI server pushing building owners to make a buck off their idle solar power. These self-contained, 8-GPU NVIDIA cabinets don't just sit pretty; they’re money-makers, potentially turning an overlooked asset into a goldmine. If your building's solar panels are just loafing about...

CoCo Expands Bubble Tea Empire: Hungary to Ukraine

CoCo's Three-Market Strategy Dive into the world of bubbly enthusiasm: CoCo Bubble Tea is making a splash in Central and Eastern Europe, targeting Hungary, Armenia, and gearing up for Ukraine. No small feat, this move taps straight into the heart of younger consumers who can't get enough of quirky, customizable Asian-inspired drinks. We're not only talking tea—this is a...